From Precision Medicine to Real-World AI Implementation: 5 Emerging Companies Share Practical Insights
On the afternoon of November 17, a themed salon titled “Predicting the Development Trends of Precision Medicine and Medical AI in 2018” was held at Beijing Health Intelligence Valley. The event was moderated by Li Datao, founder of VCBeat.
This salon event will discuss the hottest topics in the field of medical big data, divided into two modules: real-world corporate practical experiences, and how enterprises can respond to significant industry transformations in the context of precision medicine and artificial intelligence.
Gao Chongwu, Marketing Director at Remebot
Gao Chongwu, Marketing Director at Baihui Weikang, stated: “In 1998, while pursuing his doctoral degree, Baihui Weikang’s founder, Liu Da, joined the surgical medical robotics research group established by his supervisor, Professor Wang Tianmiao. Serving as the technical lead, he successfully secured a project under the National ‘863 Program’ that year.”
The company’s flagship product is a neurosurgical robot that enables physicians to perform minimally invasive, precise, and efficient frameless stereotactic surgeries. The average procedure time is only 30 minutes, with a localization accuracy of 1 mm, leaving patients with a single incision no larger than 2 mm. The company holds a monopolistic position in this technology within China and has achieved numerous firsts in the clinical application of surgical robots domestically: it was the first to be successfully applied in clinical practice, the first to successfully perform remote surgery, and the first robotic surgical procedure to be included in designated medical insurance coverage.
Zheng Naizhong, Vice President of Meiyin Gene
Zheng Naizhong, Vice President of Meinian Gene, stated, “The company was founded and invested in by Mr. Yu Rong, Chairman of Meinian Onehealth Healthcare. Our core team members hail from prestigious institutions such as Peking University, the University of Oxford, and the Chinese Academy of Sciences, bringing extensive professional and entrepreneurial experience from renowned domestic and international gene sequencing enterprises. We are continuously developing genetic testing products focused on preventive care, including susceptibility gene testing, early cancer screening, pharmacogenomic testing, and microbiome genetic testing, to benefit the general public. The company has established a high-standard laboratory platform in accordance with medical laboratory requirements, upholding the vision of ‘Genetic Technology for a More Beautiful and Healthier Humanity’ to help individuals achieve precise health management.”
Yihuo Bio’s Vice President, Zhang Chenguang
Yihuo Bio’s Vice President, Zhang Chenguang, stated: “EFIRM, a technology independently developed by Yihuo Bio, fills a gap in the current field of genetic testing. The emergence of EFIRM has established a tripartite landscape in genetic testing, with PCR, NGS, and EFIRM each occupying a share of the market. Moreover, EFIRM is the only platform whose core technologies are entirely mastered by Chinese developers.”
The specific advantages of EFIRM technology and products are as follows:
More Precise: Accuracy Exceeds 95%;
More efficient: results available in just 60 minutes;
Greater Convenience: The testing equipment can be fully automated, and even when operated manually, it remains very simple to use; portable versions of the testing equipment can even be produced.
More cost-effective: The expected price is one-tenth that of current diagnostic methods.”
Xu Changjun, Chairman of Julu Medical
Xu Changjun, Chairman of Julu Medical, stated: “Julu Medical is a company specializing in healthcare management, dedicated to improving people’s quality of life through innovative care models. By integrating the Feiyisheng App, smart hardware, and offline care centers, we achieve comprehensive monitoring of chronic respiratory diseases. The smart hardware paired with the app features chronic respiratory disease monitoring capabilities; it is compact and portable, enabling rapid and convenient detection of multiple indicators related to chronic respiratory conditions.”
Meanwhile, the Fei Doctor App can record and analyze data collected by hardware devices to detect user abnormalities at an early stage, facilitating disease prevention, treatment, and rehabilitation. Furthermore, the company collaborates with hospitals to establish care centers, providing users with offline medical services.
“Xu Changjun stated that the company will also collect and organize user data from its products in the future, and use this as a basis to provide more comprehensive services for patients with chronic respiratory diseases.”
Qin Tieling, Vice President of Holistic Care
Qin Tieling, Vice President of Quan Cheng Guan Ai, stated: “Quan Cheng Guan Ai is an innovative service company dedicated to providing high-quality professional medical solutions and comprehensive disease management services. Leveraging robust expert resources, mobile internet technology, and the latest global diagnostic and therapeutic methods, the company offers a premium annual membership-based private physician service for cardiovascular specialties. This service includes regular specialist examinations, expert outpatient consultations, mobile health management, and expert evaluations.”
The company is committed to building a professional team of top-tier physicians from Xinmei, partnering with renowned domestic chain healthcare service providers, and leveraging mobile internet resources along with an experienced medical service team to deliver personalized, comprehensive healthcare solutions for our clients.
Li Hongli, Director of the Health Intelligence Valley Incubator, introduced to the audience the development status, business model, ecosystem, and future strategic layout of Health Intelligence Valley.
Health Intelligence Valley focuses on investment and incubation in the healthcare industry. Leveraging the core industrial resources of Tianyi Group and Meinian Onehealth, and driven by the concept of integrated development among government, industry, academia, research, and application, it achieves innovations in precision medicine technology and healthcare service models, as well as the development of health big data platforms and applications. It aims to build a specialized, refined, distinctive, and innovative industrial cluster in healthcare, thereby supporting regionally driven innovation-led development. By integrating healthcare industry resources, enhancing operational synergy across projects, improving customer experience, and strengthening the influence of its brand matrix, it establishes a comprehensive whole-industry-chain ecosystem.
Health Intelligence Valley has innovatively created four major models: the “Mass Entrepreneurship and Innovation” Edition, the “Ecological” Health Industry Town, the “Boutique” Health Intelligence Valley Commercial Street Store, and the “Micro” Health Intelligence Valley Institute/Hospital Edition. It has deeply cultivated a strategic layout across five major parks in Beijing, Shanghai, Hangzhou, Shanghai Jiading, and Chongqing, along with an office in Silicon Valley. In the near future, the Chengdu Health Intelligence Valley and Wuhan Health Intelligence Valley will also be launched successively.
Subsequently, moderator Li Datao conducted in-depth interviews based on the guests’ introductions, sharing real-world corporate experiences and discussing how enterprises can adapt to current trends and navigate profound industry transformations in the context of precision medicine and artificial intelligence.
Finally, the event concluded with lively exchanges between the on-site audience and the five guests.
This event is hosted by Health Intelligence Valley, with co-organizers VCBeat and Beike Society.